Is natalizumab overshooting its rebound?

被引：9

作者：

Fox, Robert J. ^{[1
]}

Kappos, Ludwig ^{[2
]}

机构：

[1] Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis, Cleveland, OH 44195 USA

[2] Univ Basel Hosp, Res Dept, Basel, Switzerland

来源：

NEUROLOGY | 2008年 / 70卷 / 13期

关键词：

D O I：

10.1212/01.wnl.0000306415.37679.5a

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：1073 / 1074

页数：2

共 10 条

[1] The incidence and significance of anti-natalizumab antibodies -: Results from AFFIRM and SENTINEL [J].

Calabresi, P. A. ;

Giovannoni, G. ;

Confavreux, C. ;

Galetta, S. L. ;

Havrdova, E. ;

Hutchinson, M. ;

Kappos, L. ;

Miller, D. H. ;

O'Connor, P. W. ;

Phillips, J. T. ;

Polman, C. H. ;

Radue, E. -W. ;

Rudick, R. A. ;

Stuart, W. H. ;

Lublin, F. D. ;

Wajgt, A. ;

Weinstock-Guttman, B. ;

Wynn, D. R. ;

Lynn, F. ;

Panzara, M. A. ;

Macdonell, R. ;

Hughes, A. ;

Taylor, I. ;

Lee, Y. C. ;

Ma, H. ;

King, J. ;

Kilpatrick, T. ;

Butzkueven, H. ;

Marriott, M. ;

Pollard, J. ;

Spring, P. ;

Spies, J. ;

Barnett, M. ;

Dehaene, I. ;

Vanopdenbosch, L. ;

D'Hooghe, M. ;

Van Zandijcke, M. ;

Derijck, O. ;

Seeldrayers, P. ;

Jacquy, J. ;

Piette, T. ;

De Cock, C. ;

Medaer, R. ;

Soors, P. ;

Vanroose, E. ;

Vanderhoven, L. ;

Nagels, G. ;

Dubois, B. ;

Deville, M. -C. ;

D'Haene, R. .

NEUROLOGY, 2007, 69 (14) :1391-1403

[2] A controlled trial of natalizumab for relapsing multiple sclerosis. [J].

Miller, DH ;

Khan, OA ;

Sheremata, WA ;

Blumhardt, LD ;

Rice, GPA ;

Libonati, MA ;

Willmer-Hulme, AJ ;

Dalton, CM ;

Miszkiel, KA ;

O'Connor, PW .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01) :15-23

[3]

O'Connor PW, 2006, MULT SCLER, V12, pS17

[4] Randomized multicenter trial of natalizumab in acute MS relapses - Clinical and MRI effects [J].

O'Connor, PW ;

Goodman, A ;

Willmer-Hulme, AJ ;

Libonati, MA ;

Metz, L ;

Murray, RS ;

Sheremata, WA ;

Vollmer, TL ;

Stone, LA .

NEUROLOGY, 2004, 62 (11) :2038-2043

[5] A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis [J].

Polman, CH ;

O'Connor, PW ;

Havrdova, E ;

Hutchinson, M ;

Kappos, L ;

Miller, DH ;

Phillips, JT ;

Lublin, FD ;

Giovannoni, G ;

Wajgt, A ;

Toal, M ;

Lynn, F ;

Panzara, MA ;

Sandrock, AW .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) :899-910

[6] Linomide in the treatment of multiple sclerosis:: MRI results from prematurely terminated phase-III trials [J].

Tan, IL ;

Lycklama à Nijeholt, GJ ;

Polman, CH ;

Adèr, HJ ;

Barkhof, F .

MULTIPLE SCLEROSIS, 2000, 6 (02) :99-104

[7] Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE [J].

Theien, BE ;

Vanderlugt, CL ;

Nickerson-Nutter, C ;

Cornebise, M ;

Scott, DM ;

Perper, SJ ;

Whalley, ET ;

Miller, SD .

BLOOD, 2003, 102 (13) :4464-4471

[8] The effect of anti-α4 integrin antibody on brain lesion activity in MS [J].

Tubridy, N ;

Behan, PO ;

Capildeo, R ;

Chaudhuri, A ;

Forbes, R ;

Hawkins, CP ;

Hughes, RAC ;

Palace, J ;

Sharrack, B ;

Swingler, R ;

Young, C ;

Moseley, IF ;

MacManus, DG ;

Donoghue, S ;

Miller, DH .

NEUROLOGY, 1999, 53 (03) :466-472

[9] Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients [J].

Vellinga, M. M. ;

Castelijns, J. A. ;

Barkhof, F. ;

Uitdehaag, B. M. J. ;

Polman, C. H. .

NEUROLOGY, 2008, 70 (13) :1150-1151

[10] Linomide in relapsing and secondary progressive MS -: Part II:: MRI results [J].

Wolinsky, JS ;

Narayana, PA ;

Noseworthy, JH ;

Lublin, FD ;

Whitaker, JN ;

Linde, A ;

Gjörstrup, P ;

Sullivan, HC .

NEUROLOGY, 2000, 54 (09) :1734-1741

← 1 →